Filing Flows

Filing Flows › Seres Therapeutics (MCRB) › Who owns the stock

Who owns Seres Therapeutics (MCRB) stock

34 funds reported Seres Therapeutics (MCRB) shares in their latest 13F filings, worth $13.0M in all. The largest holder is Vanguard Group ($4.8M). Last quarter 13 funds added to their stakes and 15 cut them.

Largest holders of MCRB (13F)Largest holders of MCRB (13F)Vanguard Group$4.8MVanguard Capital Management LLC$2.3MMarshall Wace, LLP$1.4MBlackRock$876KGeode Capital Management, LLC$631KSusquehanna International Group, …$460KVanguard Fiduciary Trust$384KVontobel Holding$384KState Street$267KLion Point Capital, LP$249K

Largest holders (13F)

FundSharesValueChangeQuarter
Vanguard Group324,214$4.8Mincrease2025-12-31
Vanguard Capital Management LLC287,776$2.3Mdecrease2026-06-30
Marshall Wace, LLP172,245$1.4Mincrease2026-06-30
BlackRock111,000$876Kincrease2026-06-30
Geode Capital Management, LLC79,974$631Kincrease2026-06-30
Susquehanna International Group, LLP58,328$460Kdecrease2026-06-30
Vanguard Fiduciary Trust48,685$384Kincrease2026-06-30
Vontobel Holding114,566$384Kdecrease2026-09-30
State Street33,901$267Kunchanged2026-06-30
Lion Point Capital, LP31,570$249Kunchanged2026-06-30
Charles Schwab Investment Management31,049$245Kdecrease2026-06-30
American Century Companies28,313$223Kdecrease2026-06-30
XTX Topco20,732$164Knew2026-06-30
Goldman Sachs Group15,229$120Knew2026-06-30
Northern Trust14,765$116Kunchanged2026-06-30

Seres Therapeutics' latest quarter

Seres Therapeutics, Q3 2026: revenue $593K (+69% year over year), net loss $16.3M, operating cash flow −$10.5M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most MCRB stock?

By the latest 13F filings: Vanguard Group ($4.8M); Vanguard Capital Management LLC ($2.3M); Marshall Wace, LLP ($1.4M); BlackRock ($876K); Geode Capital Management, LLC ($631K).

What is the short interest in MCRB?

312,339 shares were sold short at the 2026-10-15 settlement, -0.61% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.